Normal Renal Function Clinical Trial
Official title:
A Phase I Pharmacokinetic Study of Genasense® in Subjects With Normal Renal Function and Mildly and Moderately Impaired Renal Function
To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02431481 -
Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011
|
Phase 1 | |
| Completed |
NCT04699877 -
A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function
|
Phase 1 | |
| Completed |
NCT04656795 -
PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
|
Phase 1 | |
| Completed |
NCT02965040 -
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function
|
Phase 1 |